skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Proton beam radiotherapy of choroidal melanoma: The Liverpool-Clatterbridge experience

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [3];  [4];  [3]
  1. Ocular Oncology Service, St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool (United Kingdom)
  2. Douglas Cyclotron, Clatterbridge Center for Oncology, Bebington, Wirral (United Kingdom)
  3. Department of Clinical Oncology, Clatterbridge Center for Oncology, Bebington, Wirral (United Kingdom)
  4. IC Statistical Services, Wirral (United Kingdom)

Purpose To report on outcomes after proton beam radiotherapy of choroidal melanoma using a 62-MeV cyclotron in patients considered unsuitable for other forms of conservative therapy. Methods and Materials A total of 349 patients with choroidal melanoma referred to the Liverpool Ocular Oncology Centre underwent proton beam radiotherapy at Clatterbridge Centre for Oncology (CCO) between January 1993 and December 2003. Four daily fractions of proton beam radiotherapy were delivered, with a total dose of 53.1 proton Gy, and with lateral and distal safety margins of 2.5 mm. Outcomes measured were local tumor recurrence; ocular conservation; vision; and metastatic death according to age, gender, eye, visual acuity, location of anterior and posterior tumor margins, quadrant, longest basal tumor dimension, tumor height, extraocular extension, and retinal invasion. Results The 5-year actuarial rates were 3.5% for local tumor recurrence, 9.4% for enucleation, 79.1% for conservation of vision of counting fingers or better, 61.1% for conservation of vision of 20/200 or better, 44.8% for conservation of vision of 20/40 or better, and 10.0% for death from metastasis. Conclusion Proton beam radiotherapy with a 62 MeV cyclotron achieves high rates of local tumor control and ocular conservation, with visual outcome depending on tumor size and location.

OSTI ID:
20698498
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 62, Issue 5; Other Information: DOI: 10.1016/j.ijrobp.2005.01.016; PII: S0360-3016(05)00131-8; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Visual acuity after Ruthenium{sup 106} brachytherapy of choroidal melanomas
Journal Article · Sat Oct 01 00:00:00 EDT 2005 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20698498

Alternative Dose for Choroidal Melanoma Treated With an Iodine-125 Radioactive Plaque: A Single-Institution Retrospective Study
Journal Article · Mon Nov 01 00:00:00 EDT 2010 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20698498

Local Tumor Control, Visual Acuity, and Survival After Hypofractionated Stereotactic Photon Radiotherapy of Choroidal Melanoma in 212 Patients Treated Between 1997 and 2007
Journal Article · Thu Sep 01 00:00:00 EDT 2011 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20698498